Femara

DRAGON PHARMA FEMARA

Femara, with the generic name letrozole, is a prescription medication belonging to the class of aromatase inhibitors. It is utilized in the treatment of hormone receptor-positive breast cancer in postmenopausal women.

DRUG COMPOSITION

The active ingredient in Femara is letrozole. Each Femara tablet contains 2.5 mg of letrozole, contributing to its pharmacological effects.

PHARMACEUTICAL FORM

Femara is commonly available in oral tablet form. The tablets are intended for oral administration and should be taken as directed by a healthcare professional.

PHARMACEUTICAL GROUP AND ATC CODE

Femara is classified within the pharmacotherapeutic group of antineoplastic agents, specifically aromatase inhibitors (ATC code: L02BG04).

PHARMACOLOGICAL PROPERTIES

Letrozole, the active ingredient in Femara, inhibits the aromatase enzyme, leading to a reduction in estrogen production. This is particularly beneficial in treating estrogen-dependent breast cancer.

PROFILE

• Chemical name: 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
• Chemical formula: C17H11N5
• Percentage of anabolic activity: Not a steroid
• Percentage of androgenic activity: Not a steroid
• Active half life: 2 days
• Recommended dosage: 0.5-2.5 mg/day
• Acne: no
• Bloating (water retention): no
• HBR: no
• Hepatic toxicity: no
• Aromatization: no

THERAPEUTICAL INDICATIONS

Femara is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also used in extended adjuvant treatment following five years of tamoxifen therapy.

DOSES AND METHOD OF ADMINISTRATION

The dosage of Femara is determined by the treating healthcare provider based on the specific type and stage of breast cancer. It is typically taken orally once a day, with or without food.

CYCLE/STACKING

In breast cancer treatment, Femara is often prescribed in cycles, with the duration and timing tailored to the individual's response to therapy. The cycle may extend over several weeks or months.

POST CYCLE THERAPY

Femara is not typically used in post-cycle therapy for anabolic steroid users. Its role is primarily in the treatment of breast cancer.

SIDE EFFECTS

Common side effects of Femara may include hot flashes, joint pain, fatigue, and nausea. Serious side effects are rare but may include bone density loss and an increased risk of fractures.

CONTRAINDICATIONS

Femara is contraindicated in premenopausal women, individuals with a known hypersensitivity to letrozole, and those with a history of osteoporosis or severe liver impairment.

OVERDOSE

In case of an overdose, medical attention should be sought promptly. There is no specific antidote, and treatment is supportive.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE:

Patients taking Femara should be monitored for bone health, and bone density assessments may be recommended. Letrozole may cause fetal harm and is not indicated for use during pregnancy.

INTERACTIONS WITH OTHER DRUGS

Certain medications may interact with Femara, and it is important to inform the healthcare provider of all medications being taken, including over-the-counter drugs and supplements.

PRESENTATION, PACKAGING

100 tablets in sachet.

STORAGE

Femara should be stored at room temperature, away from light and moisture. It should be kept out of reach of children.

DELIVERY TO THE USA

Femara is available for secure and discreet delivery to the USA through authorized supplier - Steroid.biz.

LEGAL STATUS

Femara is a prescription medication and is subject to regulatory controls to ensure proper use under medical supervision. It is not available over-the-counter and should only be used as directed by a qualified healthcare professional.

LAB TEST RESULTS

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma
Europe

EXTERNAL LINKS

• Letrozole Wiki, wikipedia.org
• Letrozole Uses, Side Effects & Warnings, drugs.com
• Letrozole Oral: Uses, Side Effects, Interactions, Pictures, medlineplus.gov.